Hemostatic-management-study-shows-lower-blood-use-and-less-kidney-injury-with-PCC-than-plasma-after-heart-surgery ...
PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
The American Journal of Managed Care® discussed an indirect comparison of andexanet alfa and prothrombin complex concentrate therapy with Alexander T. Cohen, MBBS, MSc, MD, Guy’s and St Thomas’ ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...
What is Kcentra®/4-factor Prothrombin Complex Concentrate? Kcentra® (4-factor Prothrombin Complex Concentrate), is a blood clotting factor replacement product. It contains clotting factors II, VII, IX ...
The Center for Injury Science (CIS) at UAB has partnered with CSL Behring to support the management of one of the largest ever trauma clinical trials. The Trauma and Prothrombin Complex Concentrate ...
Bleeding out, or the rapid loss of blood, is the most common cause of preventable death after injury. Researchers at Baylor College of Medicine and Ben Taub Hospital, part of Harris Health System, are ...
Credit: Getty Images. Balfaxar is a non-activated 4 factor prothrombin complex concentrate containing vitamin K-dependent factors. The Food and Drug Administration (FDA) has approved Balfaxar ® ...
To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted ...
Among over 300 patients with the highest trauma level activation, the absolute difference in median total 24-hour blood product consumption between the 4F-PCC and placebo groups was 0.2 U (95% CI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results